DOSE-RESPONSE CURVES FOR AGENTS THAT
Received for publication November 19, 1968 AGENTS that act mainly by impairing cell reproductive integrity inevitably damage proliferating populations of normal cells, such as those of the bone marrow or intestinal epithelium. The main clinical problem in using such agents to treat neoplasms or suppress unwanted immunological responses is therefore one of selectivity. Much effort is being devoted to means of improving the selectivity of antitumour and immunosuppressive agents. The purpose of this communication is to show that the relative selectivity of these agents for various cell types is not an unalterable characteristic of the agent but may depend to a considerable extent on the therapeutic schedule, that is, the size and frequency of doses.
In the preceding paper (Berenbaum, 1969) it was shown that the dose-response curves of several clinically useful agents were either exponential or hyperbolic. Simple exponential curves are described by the equation (1) where F is the surviving fraction of the cell population, 1) the dose of agent, and a a constant giving the slope of the curve. Examples of such curves are the survival of mouse lymphoma cells after irradiation (Bush and Bruce, 1964) , of L1210 cells after treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (Skipper, Schabel and Wilcox, 1965) , and of haemopoietic stem cells after treatment with cyclophosphamide (Bruce, Meeker and Valeriote, 1966) .
More usually, exponential curves have a shoulder, due possibly to multiplicity of cell targets or to repair mechanisms, or both. Extrapolation of the straight portion of the curve to the zero ordinate gives a value of F greater than 1, termed the extrapolation number. An equation generating curves approximating to those found experimentally is F 1
(1 e-D)Dl (2) where / is the extrapolation number.
The equation for hyperbolic dose-response curves, such as those given by antimetabolites, is
where Do is the threshold dose and y the slope of the curve. statistical sense, single populations in respect of sensitivity to the agent and rate of proliferation or of recovery after depletion. The first case is that of a population proliferating exponentially and asynchronously without homoeostatic controls. This case may be typified by some murine leukaemias. The second case is that of a population growing according to the Gompertz equation, its growth rate decreasing continuously from the start until the population reaches a plateau. This case is typified by a large number of solid and ascitic tumours (Laird 1964 (Laird , 1965 . The third case is that of a population maintained at a steady-state level by homoeostasis. Many normal populations, e.g. bone marrow, behave in this way, but it must be pointed out that probably no cell population quite fits the model prescribed here, for homoeostasis usually implies the existence of precursor cell compartments and so of inhomogeneity in the population. However, multicompartment analysis is outside the scope of this paper and the single compartment case is sufficiently instructive to warrant examination.
The aim of therapy in cancer is generally to eliminate certain populations of the first two types (leukaemic and tumour cells), while conserving at tolerable levels populations of the third type (bone marrow, intestinal epithelium, etc.).
The therapeutic regimens to achieve these aims for each type of population will be considered in turn.
Exponentially Growing Populations
If the population doubling time is T, the increase in cell number from N0 to N1 in time t is given by Nt = No 2t/T
Suppose a dose D of an antineoplastic agent reduces the population to a fraction F, then, after n such doses at intervals t, the net surviving fraction S is given by S = [F.2t /T]n (5) If the product F. 2tT exceeds 1, the population will continue to grow in spite of repeated depletions. If it is less than 1, the population will decline progressively and will be eliminated when less than one cell is left, i.e. when S is less than the reciprocal of the initial number of cells. This principle is illustrated in Fig. 1 Laird (1964 Laird ( , 1965 This principle is illustrated in Fig. 2 where it is shown that cells growing at the fastest rate permitted by equation (6) (7), (9) and (10) describe the fates of the three types of population with reference to the fractional reduction F caused by each dose and the interval between doses t. In order to determine the effects of particular regimens we now substitute for F in these equations the expressions in equations (1), (2) Table I gives the equations so derived.
A concrete example will show how these formulae may be used to design selective dose regimens. Suppose we wished to treat a leukaemic individual with an antimetabolite that gave hyperbolic dose-response curves with both leukaemic and normal granulopoietic cells. It will be assumed that the leukaemic cells are proliferating exponentially and therefore this population will be eliminated if the Table I and T and k (the proliferative or recuperative characteristics of the cells concerned).
We can then plot D against t for both equations and simply read the required regimens (if they exist) from the graph. This has been done in Fig Skipper, Schabel and Wilcox (1964) . The relevant parameters for normal haemopoietic cells are not known with such certainty. Dose-response curves for actively proliferating bone marrow are considerably steeper than those from normal marrow, which contains a significant proportion of resting cells (Bruce, 37 Meeker and Valeriote, 1966; Bruce and Meeker, 1967) . Depletion of the normal marrow population by the first few doses of agent would tend to induce rapid proliferation in the remaining cells. It is appropriate, therefore, to base a regimen of repeated doses on parameters measured when the cells are actively proliferating. A log-log plot of Bruce and Meeker's (1967) data for rapidly proliferating marrow cells suggests a Do for 5-fluorouracil of about 10 mg./kg. and a value of 1-7 for y. Consideration of published data on recovery of marrow cells after depletion suggests 0-25 -2 day-' as the usual range of values for k, and a value of 0.5 has been selected for this example. In Fig. 5 the leukaemic cells would be progressively reduced in number by all regimens of 5-fluorouracil above and to the left of curve A, and the population of normal haemopoietic cells would remain above 0 5 of its normal size under all regimens below and to the right of curve B. Regimens with the required selectivity are therefore those in the shaded area of the figure.
Consider, for instance, a regimen of 11 mg./kg. of fluorouracil given daily. The size of the leukaemic cell population after n doses will be 0-77n (equations 3 and 5). After 70 doses it will be about 10-8 of its original size, and continued therapy will eventually eliminate it altogether. The population of normal haemopoietic cells, on the other hand, should settle down to a steady-state level of about 0 75 of its normal size under continued therapy (equations 3 and 10). This regimen therefore has the required specificity. Now take an incorrectly chosen regimen, say, 33 mg./kg. given every 3 days. From equations (3), (5) and (10) it can be seen that this regimen eliminates the normal cells (F 0-13 < e-kt _ 0-22), yet it allows the leukaemic cell population to grow, although at a slower rate than in an untreated individual (this population increases by a factor of 1 48 between each dose). It should be noted that, in this example, the overall dosage in a given time is the same as that in the regimen with the desired selectivity; only the size and frequency of the individual doses have been changed. Evidently, such simple changes in regimen may radically alter the selectivity of action of a drug, and may make all the difference between a treatment that is useful and one that is disastrous. The small probability of picking by chance a regimen with the required selectivity in this example is also clear from Fig. 5 , and this is relevant, not only to therapy, but to the screening of new drugs. Now consider the design of therapeutic regimen aimed at destroying a solid tumour growing according to equation (6) , using an alkylating agent giving exponential dose-response curves with tumour cells and normal haemopoietic cells. It will be assumed that the dose-response curve for normal haemopoietic cells is that given by Bruce, Meeker and Valeriote (1966) for cyclophosphamide. This is a simple exponential curve without a shoulder, the value of a being 0-63. The value of k will be taken as 0 5 as in the previous example. There are no adequate available data from which to derive the parameters of the dose-response curves for solid tumours; we shall here assume that the particular tumour cells in question are highly sensitive and give an exponential dose-response curve with a shoulder when treated with the agent, the value of ac being 0.7 and of fi, 5. Typical values for the Gompertz equation parameters a and b are 0-2 and 0-02 (Laird, 1964 (12) and (13) , has a simple exponential form (Bruce, Meeker and Valeriote, 1966) , so equation G in Table I is used; ax = 0-63, k = 0-5 day-'. It is assumed that the dose-response curve for tumour cells (population A) has a shoulder and that the relevant values (equation E, Table I) are a = 0-7, # = 5, a = 0-2, b = 0-02. Regimens that will eliminate the tumour and conserve normal haemopoietic cells are in the shaded area.
In practice, relatively few cell populations can be expected to behave in the simple ways here described. Tissues such as the leucopoietic or erythropoietic fractions of the bone marrow have to be considered as multi-compartment systems and not homogeneous populations (Lajtha, Oliver and Gurney, 1962; Lajtha, Gilbert, Porteous and Alexanian, 1964; Lajtha, 1968) . If, for example, the cells of a precursor compartment were more sensitive to the agent or recovered more slowly after depletion than the cells of the compartment being studied, the latter could be depleted far more by a prolonged dose regimen than would be suggested by consideration of its dose-response curve and recuperative properties after single doses of agent.
Considerable complexity would also be introduced by the existence of a nongrowing fraction, such as occurs in many tumours (Mendelsohn, 1963) . Inhomogeneity might also arise from the presence of a small fraction of proliferating cells relatively resistant to the agent, as is suggested, for example, by the tendency of the dose-response curves for methotrexate and thioguanine to flatten out at high doses (Berenbaum, 1969, Fig. 2) . If this resistance is characteristic of a particular phase of the cell cycle it would probably not materially affect the considerations advanced here, provided the doses used were in the range where the dose-response curve is straight and the dosage interval was not in phase with the cell cycle (Merkle, Stuart and Gofman, 1965; Stuart and Merkle, 1965) . If, on the other hand, high resistance were a genetic property of a particular fraction of the population, then the properties of the population would change during treatment, and dose-response curves based on experiments with single doses would become progressively less valid with increasing length of treatment.
There is evidently a need for a more sophisticated mathematical analysis than that outlined in this paper, and for more comprehensive experimental data on which to base it. Nevertheless, the simplified approach adopted here suggests that manipulations of the therapeutic schedule may influence not only the magnitude and speed of the effect of an agent on particular cell types but also its selectivity of action for these various types. The clinical relevance of this conclusion requires no emphasizing.
These considerations also underline the importance of the dose regimen in the clinical trial of antitumour and immunosuppressive agents. The examples shown in Fig. 5 and 6 suggest that some drugs rejected after poor performance in clinical trials might have appeared in a different light had different dose schedules been used. The practical problems involved in the satisfactory trial of a new agent are so large, however, that the thorough testing of a variety of dose schedules for each agent is hardly practicable with present resources. The alternative approach, which would supplement information obtained clinically, entails the intensive study of those cell characteristics responsible for selectivity of drug action, the determination of dose-response curves for cell types of clinical importance, and the measurement of other factors (generation times, growth and differentiating fractions, parameters of homoeostasis, etc.) that influence the overall effect of drugs on particular tissues. The difficulties of this approach are formidable, but the possibility of rationally designing therapeutic regimens of relatively high selectivity against neoplastic or immunologically active cells is sufficient inducement to attempt this task.
SUMMARY
In a simplified model, the fate of growing or steady-state cell populations under a regimen of repeated doses of a cell-sterilizing agent may be predicted from equations containing two types of parameter-(1) those determined by the dose-response curve and the proliferative or recuperative characteristics of the cell populations and (2) those determined by the therapeutic regimen (i.e. size, frequency and number of doses). Ifthe values ofthe former are known, those of the latter may be adjusted to ensure either destruction or survival of the cell population. Different cell types show different dose-response curves to the same agent and have different proliferative or recuperative rates. Regimens may therefore be chosen that selectively damage one cell population while allowing another in the same individual to survive. The model suggests that, in some circumstances, the fates of two cell populations in the same individual may be reversed by manipulating the therapeutic regimen. 
